Sodium channel blockers in Brugada syndrome

Europace. 2018 Jun 1;20(FI1):f139. doi: 10.1093/europace/euy084.

Authors

Ibrahim El-Battrawy^{1

2}, Martin Borggrefe^{1

2}, Siegfried Lang^{1

2}, Xiaobo Zhou^{1

2}, Ibrahim Akin^{1

2}

Affiliations

¹ First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.
² DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.

PMID: 29878207
DOI: 10.1093/europace/euy084

No abstract available

Publication types

Letter
Comment

MeSH terms

Ajmaline
Brugada Syndrome*
Flecainide*
Humans
Sodium Channel Blockers
Syncope

Substances

Sodium Channel Blockers
Ajmaline
Flecainide